275 related articles for article (PubMed ID: 24120761)
1. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.
Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM
Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into neonatal Fc receptor-based recycling mechanisms.
Oganesyan V; Damschroder MM; Cook KE; Li Q; Gao C; Wu H; Dall'Acqua WF
J Biol Chem; 2014 Mar; 289(11):7812-24. PubMed ID: 24469444
[TBL] [Abstract][Full Text] [Related]
3. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
Andersen JT; Daba MB; Sandlie I
Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
[TBL] [Abstract][Full Text] [Related]
4. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
5. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
[TBL] [Abstract][Full Text] [Related]
6. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the complex of rat neonatal Fc receptor with Fc.
Burmeister WP; Huber AH; Bjorkman PJ
Nature; 1994 Nov; 372(6504):379-83. PubMed ID: 7969498
[TBL] [Abstract][Full Text] [Related]
8. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
Yang B; Kim JC; Seong J; Tae G; Kwon I
Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
[TBL] [Abstract][Full Text] [Related]
10. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
[TBL] [Abstract][Full Text] [Related]
12. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
13. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.
Andersen JT; Dalhus B; Cameron J; Daba MB; Plumridge A; Evans L; Brennan SO; Gunnarsen KS; Bjørås M; Sleep D; Sandlie I
Nat Commun; 2012 Jan; 3():610. PubMed ID: 22215085
[TBL] [Abstract][Full Text] [Related]
14. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
[TBL] [Abstract][Full Text] [Related]
15. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
Andersen JT; Dee Qian J; Sandlie I
Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
[TBL] [Abstract][Full Text] [Related]
16. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
[TBL] [Abstract][Full Text] [Related]
17. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
18. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies.
Sand KM; Dalhus B; Christianson GJ; Bern M; Foss S; Cameron J; Sleep D; Bjørås M; Roopenian DC; Sandlie I; Andersen JT
J Biol Chem; 2014 Jun; 289(24):17228-39. PubMed ID: 24764301
[TBL] [Abstract][Full Text] [Related]
19. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
20. Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions.
Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G
Protein Sci; 2019 Nov; 28(11):1982-1992. PubMed ID: 31583777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
